MC2-01乳膏国内Ⅲ期临床试验获批 华东医药外用制剂领域再添猛将

Core Viewpoint - Huadong Medicine's subsidiary has received approval for the Phase III clinical trial of MC2-01 cream for treating plaque psoriasis in China, marking a significant step towards clinical application and enhancing the company's portfolio in immune skin preparations [1][2][3]. Group 1: Product Development and Market Potential - MC2-01 cream is a fixed-dose combination of calcipotriene and betamethasone for local treatment of adult plaque psoriasis, utilizing a unique drug delivery system that improves patient convenience and comfort [2][3]. - The psoriasis treatment market in China is rapidly growing, with projections estimating it will reach $3.25 billion by 2025 and further increase to $9.94 billion by 2030, indicating substantial market potential [2]. - Approximately 80%-90% of psoriasis patients globally have the plaque type, with a projected 6.168 million patients in China by 2030, highlighting the urgent need for effective treatment options [3]. Group 2: Competitive Positioning and Product Pipeline - Huadong Medicine has established a comprehensive pipeline in the autoimmune field, with over 20 innovative products under development, covering various conditions including psoriasis, atopic dermatitis, and more [4]. - The company has formed a "golden product combination" in psoriasis treatment, including monoclonal antibodies, oral, and topical formulations, aiming to provide a full spectrum of treatment options for both children and adults [5]. - The company is also advancing its collaboration with Arcutis on roflumilast cream, which has shown positive efficacy and safety in treating plaque psoriasis in patients aged 6 and above, with plans for a Chinese market application [6]. Group 3: Strategic Innovations and Future Outlook - Huadong Medicine is actively expanding its research and development in GLP-1 receptor agonists, with recent patents granted in both China and the U.S., indicating a strategic focus on metabolic diseases [6]. - The company aims to become a globally influential innovative pharmaceutical enterprise, continuously driving high-quality development in China's pharmaceutical innovation landscape [7].